NCT02927925 - A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

January 2, 2020

Study Completion Date

January 7, 2020

Conditions

Lymphoma

Interventions

DRUG

Daratumumab

Participants will receive daratumumab 16 mg/kg as intravenous infusion.

Trial Locations (17)

3080

Seoul National University Hospital, Seoul

5505

Asan Medical Center, Seoul

10002

National Taiwan University Hospital, Taipei

10408

National Cancer Center, Goyang-si

40447

China Medical University Hospital, Taichung

50006

Changhua Christian Hospital, Changhua

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

169608

Singapore General Hospital, Singapore

169610

National Cancer Centre Singapore, Singapore

200025

Ruijin Hospital, Shanghai Jiao Tong University, Shanghai

310003

1st Affiliated Hospital of Zhejiang University Medical College, Hangzhou

510060

Sun Yat-Sen University Cancer Center, Guangzhou

Unknown

Queen Mary Hospital, University of Hong Kong, Hong Kong

03722

Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

06591

Seoul St. Mary's Hospital, Seoul

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY